| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Alanine derivative
This compound does not have a specific biological target; it is a chemical building block. As an alanine derivative, it is used in peptide synthesis and medicinal chemistry. It is a chiral molecule with significant interest in organic chemistry and pharmaceuticals. |
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not have direct in vitro biological activity. Its value is chemical, serving as a protected amino acid intermediate. Amino acids and their derivatives have been commercially used as ergogenic supplements. |
| ln Vivo |
This compound is not used in in vivo studies as a therapeutic agent. It is a research chemical used as a building block in organic synthesis. The final synthetic product, not this intermediate, would be the subject of in vivo testing.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable as this compound is not a drug. Its use is in organic synthesis. It can be used as a building block in the synthesis of pharmaceuticals and other chiral compounds.
|
| Cell Assay |
This compound is not used in cell-based assays. Its applications are in synthetic chemistry. Its molecular formula is C₁₅H₂₁NO₄. It is an alanine derivative and a chiral compound.
|
| Animal Protocol |
In vivo, this compound is not administered as a drug. It is a research chemical. It may be used in animal studies as a precursor or building block for other compounds, but it is not a therapeutic agent itself.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this is not a drug. It is a small molecule with the formula C₁₅H₂₁NO₄. Its properties are relevant for chemical handling and storage. It is an alanine derivative.
|
| Toxicity/Toxicokinetics |
The toxicity of this compound is not extensively documented. As a research chemical, it should be handled with standard laboratory precautions. It is not intended for human or veterinary use. The specific target is Amino Acid Derivatives.
|
| References | |
| Additional Infomation |
Nutritional enhancers have long been used to improve athletic and competitive performance. A wide variety of dietary ingredients with enhancing effects are widely used by athletes. However, these ingredients are frequently subject to legal scrutiny due to their claimed benefits and safety concerns. Amino acid derivatives are widely touted as adjuvants that can effectively enhance physical and mental performance in multiple ways, but research suggests that individuals with amino acid deficiencies are more likely to benefit from amino acid derivative supplements than those with normal deficiencies. This article reviews some of the most common and widely used amino acid derivatives in sports and competitive sports, including creatine, tyrosine, carnitine, HMB, and taurine, and explores their effects on athletic performance, mental activity, and physical strength and composition. Creatine, carnitine, HMB, and taurine have been reported to delay the onset of fatigue and improve athletic performance and physical strength. HMB helps increase lean body mass and reduce exercise-induced muscle damage. Taurine has been found to reduce oxidative stress during exercise and has a blood pressure-lowering effect. While studies have not yet found any beneficial effects of tyrosine on athletic performance, it has been shown to effectively combat stress and improve mood and cognitive function, especially in individuals with sleep deprivation. Although published research data and results are still inconclusive regarding the efficacy of creatine, tyrosine, and HMB, more comprehensive research is needed on carnitine and taurine to provide a theoretical basis for their synergistic effects in nutritional adjustment and supplementation. [1]
(S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoic acid is a chiral alanine derivative used as a building block in organic and pharmaceutical chemistry. It is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
C15H21NO4
|
|---|---|
| Molecular Weight |
279.34
|
| Exact Mass |
279.147
|
| CAS # |
82717-96-2
|
| PubChem CID |
5702571
|
| Appearance |
Typically exists as White to off-white solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
441.2±45.0 °C at 760 mmHg
|
| Melting Point |
150-152 °C(lit.)
|
| Flash Point |
220.6±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.524
|
| LogP |
2.74
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
20
|
| Complexity |
313
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[C@H](C(=O)OCC)(N[C@@H](C)C(=O)O)CCC1C=CC=CC=1
|
| InChi Key |
CEIWXEQZZZHLDM-AAEUAGOBSA-N
|
| InChi Code |
InChI=1S/C15H21NO4/c1-3-20-15(19)13(16-11(2)14(17)18)10-9-12-7-5-4-6-8-12/h4-8,11,13,16H,3,9-10H2,1-2H3,(H,17,18)/t11-,13-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid
|
| Synonyms |
82717-96-2; (S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoic acid; N-[(S)-(+)-1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanine; N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine; UNII-10SZ4IJ77B; (2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid; 10SZ4IJ77B;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5799 mL | 17.8993 mL | 35.7987 mL | |
| 5 mM | 0.7160 mL | 3.5799 mL | 7.1597 mL | |
| 10 mM | 0.3580 mL | 1.7899 mL | 3.5799 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03386617
Conditions:Breast CancerLink: https://clinicaltrials.gov/ct2/show/NCT04817189
Conditions:Chemotherapy-induced Nausea and VomitingLink: https://clinicaltrials.gov/ct2/show/NCT07254416
Conditions:Breast Cancer Patients Treated With T-DXd
Title:Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
Status:Recruiting
updateDate:2024-12-10
Ctid:NCT06726291
Link: https://clinicaltrials.gov/ct2/show/NCT06726291
Conditions:Endometrial CancerLink: https://clinicaltrials.gov/ct2/show/NCT06417567
Conditions:General Anesthesia Gastrointestinal Cancer SurgeryProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
